Malignant neoplasm of stomach
Gilead and Arcus Report Positive Results for TIGIT Approach in Gastric Cancer Trial
Gilead; Arcus; TIGIT; Gastric Cancer; Domvanalimab; Zimberelimab
AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025
AstraZeneca; ESMO 2025; cancer care; pivotal trials; oncology; Datopotamab deruxtecan (Datroway); Enhertu (trastuzumab deruxtecan); Imfinzi (durvalumab); triple-negative breast cancer; bladder cancer; gastric cancer; overall survival; antibody-drug conjugates
Ono’s BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial
ONO-4578; EP4 antagonist; gastric cancer; Opdivo; nivolumab; Bristol-Myers Squibb; phase 2; progression-free survival; chemotherapy; HER2-negative; advanced; recurrent
Survival Benefit of Amgen’s Bemarituzumab in Gastric Cancer Attenuates at Final Analysis
Amgen; bemarituzumab; gastric cancer; Phase 3 trial; overall survival; attenuated benefit; final analysis; FORTITUDE-101; FORTITUDE-102; Zai Lab; Opdivo; nivolumab
Elevation Oncology Discontinues Lead Drug and Cuts Workforce
EO-3021, Claudin 18.2 ADC, Phase 1 trial, gastric cancer, layoffs, strategic options
Leap Therapeutics’ Stock Plummets Following Disappointing DKK1 Antibody Results in Gastric Cancer Trials
Leap Therapeutics, DKK1 Antibody, Gastric Cancer, Clinical Trials, Stock Performance
Astellas Secures FDA Approval for Vyloy, a First-in-Class Claudin-Targeted Therapy for Gastric Cancers
Astellas, Vyloy, FDA Approval, Claudin 18.2, Gastric Cancer, Gastroesophageal Junction Cancer, HER2-negative, Zolbetuximab
FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression
FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra
FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression
FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval
Astellas’ Vyloy (Zolbetuximab) Receives EU Approval for Advanced Gastric and Gastroesophageal Junction Cancer Treatment
Astellas, Vyloy, Zolbetuximab, EU Approval, Gastric Cancer, Gastroesophageal Junction Cancer, Claudin 18.2, Targeted Therapy